1719 related articles for article (PubMed ID: 15870086)
21. Does endogenous fatty acid metabolism allow cancer cells to sense hypoxia and mediate hypoxic vasodilatation? Characterization of a novel molecular connection between fatty acid synthase (FAS) and hypoxia-inducible factor-1alpha (HIF-1alpha)-related expression of vascular endothelial growth factor (VEGF) in cancer cells overexpressing her-2/neu oncogene.
Menendez JA; Vellon L; Oza BP; Lupu R
J Cell Biochem; 2005 Apr; 94(5):857-63. PubMed ID: 15669079
[TBL] [Abstract][Full Text] [Related]
22. Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression.
Menendez JA; Ropero S; Lupu R; Colomer R
Oncol Rep; 2004 Jun; 11(6):1241-52. PubMed ID: 15138562
[TBL] [Abstract][Full Text] [Related]
23. HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production.
Simeone AM; Broemeling LD; Rosenblum J; Tari AM
Oncogene; 2003 Oct; 22(43):6739-47. PubMed ID: 14555987
[TBL] [Abstract][Full Text] [Related]
24. HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer.
Benz CC; O'Hagan RC; Richter B; Scott GK; Chang CH; Xiong X; Chew K; Ljung BM; Edgerton S; Thor A; Hassell JA
Oncogene; 1997 Sep; 15(13):1513-25. PubMed ID: 9380403
[TBL] [Abstract][Full Text] [Related]
25. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells.
Menendez JA; Vazquez-Martin A; Colomer R; Brunet J; Carrasco-Pancorbo A; Garcia-Villalba R; Fernandez-Gutierrez A; Segura-Carretero A
BMC Cancer; 2007 May; 7():80. PubMed ID: 17490486
[TBL] [Abstract][Full Text] [Related]
26. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
Seoane S; Montero JC; Ocaña A; Pandiella A
J Natl Cancer Inst; 2010 Sep; 102(18):1432-46. PubMed ID: 20811002
[TBL] [Abstract][Full Text] [Related]
27. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
Hirsch FR; Helfrich B; Franklin WA; Varella-Garcia M; Chan DC; Bunn PA
Clin Breast Cancer; 2002 May; 3 Suppl 1():12-6. PubMed ID: 12057039
[TBL] [Abstract][Full Text] [Related]
28. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
Chen W; Wei F; Xu J; Wang Y; Chen L; Wang J; Guan X
Int J Mol Med; 2011 Dec; 28(6):985-91. PubMed ID: 21887460
[TBL] [Abstract][Full Text] [Related]
29. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis.
Kumar-Sinha C; Ignatoski KW; Lippman ME; Ethier SP; Chinnaiyan AM
Cancer Res; 2003 Jan; 63(1):132-9. PubMed ID: 12517789
[TBL] [Abstract][Full Text] [Related]
30. A novel interaction between HER2/neu and cyclin E in breast cancer.
Mittendorf EA; Liu Y; Tucker SL; McKenzie T; Qiao N; Akli S; Biernacka A; Liu Y; Meijer L; Keyomarsi K; Hunt KK
Oncogene; 2010 Jul; 29(27):3896-907. PubMed ID: 20453888
[TBL] [Abstract][Full Text] [Related]
31. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
[TBL] [Abstract][Full Text] [Related]
32. Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma.
Ropero S; Menéndez JA; Vázquez-Martín A; Montero S; Cortés-Funes H; Colomer R
Breast Cancer Res Treat; 2004 Jul; 86(2):125-37. PubMed ID: 15319565
[TBL] [Abstract][Full Text] [Related]
33. PEA3 cooperates with c-Jun in regulation of HER2/neu transcription.
Matsui K; Sugimori K; Motomura H; Ejiri N; Tsukada K; Kitajima I
Oncol Rep; 2006 Jul; 16(1):153-8. PubMed ID: 16786139
[TBL] [Abstract][Full Text] [Related]
34. In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.
Ozbay T; Durden DL; Liu T; O'Regan RM; Nahta R
Cancer Chemother Pharmacol; 2010 Mar; 65(4):697-706. PubMed ID: 19636556
[TBL] [Abstract][Full Text] [Related]
35. Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu.
Piechocki MP; Yoo GH; Dibbley SK; Amjad EH; Lonardo F
Int J Cancer; 2006 Jul; 119(2):441-54. PubMed ID: 16470840
[TBL] [Abstract][Full Text] [Related]
36. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
[TBL] [Abstract][Full Text] [Related]
37. tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO).
Menendez JA; Vazquez-Martin A; Garcia-Villalba R; Carrasco-Pancorbo A; Oliveras-Ferraros C; Fernandez-Gutierrez A; Segura-Carretero A
BMC Cancer; 2008 Dec; 8():377. PubMed ID: 19094209
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells.
Menendez JA; Colomer R; Lupu R
Oncol Rep; 2004 Aug; 12(2):411-22. PubMed ID: 15254710
[TBL] [Abstract][Full Text] [Related]
39. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
40. The antiobesity drug Orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin) in chemoresistant ovarian cancer cells.
Menendez JA; Vellon L; Lupu R
Int J Gynecol Cancer; 2006; 16(1):219-21. PubMed ID: 16445636
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
